An inflexible price system for reimbursable medicines and inflationary pressures contributed to 1A Pharma’s decision to withdraw its popular generic paracetamol liquid from the German market, according to the company’s general manager Michael Klein.
Speaking exclusively to HBW Insight about Germany’s current children’s fever remedy supply crisis, Klein said that, despite 1A Pharma’s paracetamol suspension product being OTC, the firm – which is a subsidiary of Swiss-based
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?